Strategic Focus Target CNS and ocular haploinsufficiency programs with TANGO ASO platform to expand into related degenerative diseases, leveraging Stoke's Phase 3 zorevunersen program as a proof point for disease modification potential.

Clinical Momentum Capitalize on ongoing Phase 3 study for zorevunersen in Dravet syndrome to approach adjacent rare diseases with similar haploinsufficiency profiles, positioning for partnerships or licensing of expansion opportunities.

Growth Readiness Leverage large funding runway and mid-sized team to pursue strategic collaborations with larger biotech/pharma companies for co-development, manufacturing access, and accelerated commercialization in neurology and eye indications.

Leadership Signals Recent CSO appointment and public signaling of scientific leadership can be used to engage potential co-development partners, academic collaborations, and investor-convincing narratives around technical maturity and execution capability.

Commercial Positioning Highlight proprietary TANGO mechanism and ASO-focused biology to target companies seeking RNA-based modalities, offering collaboration on target discovery, biomarker strategies, and patient stratification in CNS and ophthalmology markets.